Clinical trials: Functional Status
Kidney Transplantation (Status Post)
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation
This is a phase 2 study to evaluate the efficacy, safety, tolerability and pharmacokinetics of GSK1070806 in subjects undergoing renal transplantation.
- Trial name
- NCT02723786
- Testing
- GSK1070806, 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Greek NIS Spiolto ELLACTO
Open-label observational study: including COPD patients receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations
- Trial name
- NCT03419962
- Testing
- MaxSpiolto® Respimat® 160 Characters...
- Where
- 15 sites in Greece
- Volunteers
- 1,360 people
- Sponsor
- Boehringer Ingelheim
Arthritis, Rheumatoid
Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
The purpose of this study is to follow the health of subjects who have previously been enrolled in studies of CP-690,550 for treatment of their rheumatoid arthritis.
- Trial name
- NCT00414661
- Testing
- CP-690,550
- Where
- 72 sites in United States, Argentina and 19 more
- Volunteers
- 162 people
- Sponsor
- Pfizer
Heart Failure
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City…
- Trial name
- CHIEF-HF (NCT04252287)
- Testing
- Canagliflozin 100 mg
- Where
- 18 sites in United States
- Volunteers
- 476 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine…
- Trial name
- NCT03165045
- Testing
- Spiolto® Respimat®
- Where
- 108 sites in Germany
- Volunteers
- 1,351 people
- Sponsor
- Boehringer Ingelheim